In recent years, some researchers performed meta-analyses to compare liraglutide and other antihyperglycaemic agents, such as sulfonylureas, insulin, TZDs, DPP-4 inhibitors and other GLP-1RAs, demonstrating different effects in lowering HbA1C/fasting plasma glucose/postprandial plasma glucose, adverse events, and improvement in insulin resistance, weight loss and the risk of hypoglycaemia [25, 26, 34, 52–57]. This evidence concerns the gene DPP4 and Insulin resistance.